PROTAC 工程化蛋白/DNA 纳米抗原是癌症免疫治疗中树突状细胞疫苗的有效增强剂
PROTAC-Engineered Protein/DNA Nanoantigen is a Potent Booster for Dendritic Cell Vaccines in Cancer Immunotherapy.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
薄荷醇纳米脂质体通过增加树突状细胞疫苗的淋巴结归巢来增强抗肿瘤免疫治疗
英文原题：Menthol nanoliposomes enhanced anti-tumor immunotherapy by increasing lymph node homing of dendritic cell vaccines.
查看英文原题
Menthol nanoliposomes enhanced anti-tumor immunotherapy by increasing lymph node homing of dendritic cell vaccines.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
薄荷醇是一种环状萜烯醇，在克服血脑屏障和角质层屏障中发挥关键作用。在此，我们创新性地提出了一种薄荷醇纳米脂质体（Men-nanoLips），可显著增加基于树突状细胞（DC）的抗肿瘤疫苗在淋巴结中的蓄积。具体而言，Men-nanoLips通过降低紧密连接蛋白的表达，有效增强了淋巴内皮细胞（EC）屏障的通透性。有趣的是，Men-nanoLips不仅上调了DCs中CCR7的表达，还增加了淋巴ECs中CCL21的分泌。此外，Men-nanoLips促进了DC疫苗的成熟，表现为共刺激分子表达的增加和伪足样蛋白的上调。凭借Men-nanoLips提供的这些互补机制，靶向引流淋巴结的B16全肿瘤细胞裂解物负载DCs的数量显著增加，并显著增强了DC抗肿瘤疫苗的治疗效果。因此，我们得出结论，Men-nanoLips可为增加DC疫苗的淋巴结归巢提供指导。
展开英文摘要原文
Menthol, a cyclic terpene alcohol, plays a critical role in overcoming the blood-brain barrier and stratum corneum barrier.
Herein, we innovatively propose a menthol nanoliposome (Men-nanoLips) that can dramatically increase lymph node accumulation of the dendritic cell (DC)-based anti-tumor vaccines. Specifically, Men-nanoLips efficiently enhanced lymphatic endothelial cell (EC) barrier permeability by reducing the expression of tight junction proteins. And interestingly, Men-nanoLips not only up-regulated the expression of CCR7 in DCs but also increased the secretion of CCL21 in lymphatic ECs.
Moreover, Men-nanoLips promoted DC vaccine maturation as evidenced by increasing the expression of costimulatory molecules and up-regulating the pseudopodia-like protein. With those complementary mechanisms provided by Men-nanoLips, the number of the B16 whole-tumor cell lysate-loaded DCs that target the draining LN enhanced remarkably and significantly boosted the treatment efficacy of DC anti-tumor vaccines.
Therefore, we concluded that Men-nanoLips could be instructive for increasing LN homing of DC vaccines.
论文信息
- 作者
- Li X、Wu Y、Wang S、Liu J、Zhang T、Wei Y、Zhu L、Bai W
- 第一作者单位
- College of Pharmacy, Shenyang Pharmaceutical University, Wenhua Road 103, 110016 Shenyang, Liaoning, China.China
- 通讯作者单位
- College of Pharmacy, Shenyang Pharmaceutical University, Wenhua Road 103, 110016 Shenyang, Liaoning, China. Electronic address: 101030124@syphu.edu.cn.China
- 文献类型
- 非美国政府资助研究
- 期刊
- Clinical immunology (Orlando, Fla.)2022 Nov
- 原文标识
- PubMed 36109005 · DOI 10.1016/j.clim.2022.109119